Cargando…
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
BACKGROUND: Tazemetostat is a selective and orally available inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and epigenetic regulator of cellular differentiation programs. We carried out a phase I study of tazemetostat in Japanese patients with relapsed or refractory B‐c...
Autores principales: | Munakata, Wataru, Shirasugi, Yukari, Tobinai, Kensei, Onizuka, Makoto, Makita, Shinichi, Suzuki, Rikio, Maruyama, Dai, Kawai, Hidetsugu, Izutsu, Koji, Nakanishi, Tadashi, Shiba, Sari, Hojo, Seichiro, Ando, Kiyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935786/ https://www.ncbi.nlm.nih.gov/pubmed/33492746 http://dx.doi.org/10.1111/cas.14822 |
Ejemplares similares
-
Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
por: Izutsu, Koji, et al.
Publicado: (2021) -
Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018) -
Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan
por: Munakata, Wataru, et al.
Publicado: (2019) -
Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2017) -
Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)